Katherine Ingrid Sprinz

Katherine Ingrid Sprinz, PhD has a diverse and extensive work experience in the field of medical affairs and scientific communications. Katherine Ingrid currently holds the position of Senior Medical Director, Hematology at Prothena Corporation plc. Prior to this, they served as the Senior Director, Medical Affairs at Fulcrum Therapeutics.

From 2020 to 2022, Dr. Sprinz worked as the Director of Global Medical Affairs at Albireo Pharma, Inc., where they were responsible for overseeing the strategic and operational aspects of the Global Medical Affairs organization. Katherine Ingrid'srole involved developing and leading various medical affairs tactics and operations, including medical leadership, scientific communications, medical information, medical training, and management.

Before joining Albireo Pharma, Dr. Sprinz held positions at Sanofi Genzyme, Bioverativ (a Sanofi company), PAREXEL, Naugatuck Valley Community College, I2I Medical Communications LLC, Pfizer Inc., and Novo Nordisk, where they gained invaluable experience in scientific communications, medical affairs, biologics program leadership, protein engineering, and international coordination.

Throughout their career, Dr. Sprinz has demonstrated strong leadership skills, strategic thinking, and a deep understanding of medical and scientific content. Katherine Ingrid has effectively managed cross-functional teams, collaborated with key stakeholders, and developed comprehensive communication strategies. Additionally, they have authored numerous publications, organized symposia, and delivered presentations at conferences.

Overall, Dr. Katherine Ingrid Sprinz's work experience showcases their expertise in the medical affairs and scientific communications field, and their ability to drive successful outcomes in diverse roles and organizations.

Katherine Ingrid Sprinz, PhD, pursued their education in the field of biology and biochemistry. Katherine Ingrid obtained a Bachelor's Degree from Cornell University between 1996 and 2000. Later, they furthered their studies at Yale University from 2000 to 2005, earning a Doctor of Philosophy (Ph.D.) in Molecular Biophysics and Biochemistry.